Skip to main content

Table 1 Clinical features and SOX2 antibody and protein staining characteristics of SCLC patients

From: Autologous anti-SOX2 antibody responses reflect intensity but not frequency of antigen expression in small cell lung cancer

  

n

Median survival (months)

P (log rank)

Age

61 (44–78)

   
 

<60

24

10.36

0.76

 

≥60

35

7.1

LDH

193 IU/L (133–380)

   
 

<200

30

10.75

0.36

 

≥200

25

8.86

 

U*

4

  

AP

93 IU/L (50-171

   
 

<70

14

3.97

0.47

 

≥70

44

8.68

 

U

1

  

Stage

Limited

28

10.36

0.03

 

Extensive

27

7.34

 

U

1

  

SOX2 antibody

<M + 2SD

42

8.68

0.3

 

≥ M + 2SD

17

7.85

SOX2 IHC intensity**

0-1

25

7.39

0.98

 

2-3

30

10.65

SOX2 IHC frequency

<5 %

16

25.87

0.12

 

≥5 %

39

7.39

SOX2 IHC frequency

<20 %

24

7.4

0.11

 

≥20 %

31

7.86

SOX2 IHC frequency

<40 %

29

7.39

0.43

 

≥40 %

26

9.68

  1. *U: unknown. **Tumor tissue sections evaluations were available from 55 patients.
Back to article page

BMC Clinical Pathology

ISSN: 1472-6890

Contact us